SightfileU.S. market data from official filings

Companies › AKTS

AKTIS ONCOLOGY INC (AKTS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002035832 · EDGAR filings · Updated 2026-07-21

AKTIS ONCOLOGY INC (AKTS) has reported institutional ownership of 65.0%, with 69 institutional managers holding positions valued at $621.0M per the latest 13F reporting period. SEC filings include an active bankruptcy or receivership filing (8-K Item 1.03), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership
65.0%
Institutional managers
69
Reported 13F value
$621.0M
Insider activity
26 trans.
$114.3M net buying
Data flags
5 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, AKTIS ONCOLOGY INC has 69 institutional holders and institutional ownership of 65.0%.

Insider activity

Insiders reported 26 transactions (9 buys, 0 sells) across 12 reporting insiders, with a net reported value of $114.3M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-11 (recurring since 2026-03-30) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2024-12-17 (recurring since 2023-10-27) — source filing. The authoritative details are those stated in the filing itself.
Active bankruptcy or receivership filing (8-K Item 1.03), most recently filed 2024-12-16 (recurring since 2024-12-16) — source filing. The authoritative details are those stated in the filing itself.
Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2024-12-16 (recurring since 2024-12-16) — source filing. The authoritative details are those stated in the filing itself.
Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2024-11-14 (recurring since 2020-01-31) — source filing. The authoritative details are those stated in the filing itself.

Related companies

AVANOS MEDICAL INC (AVNS) · AMPHASTAR PHARMACEUTICALS INC COM (AMPH) · ARBUTUS BIOPHARMA CORP (ABUS) · REPLIMUNE GROUP INC (REPL) · STEVANATO GROUP S P A (STVN) · XERIS BIOPHARMA HOLDINGS INC (XERS)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.